arabia
merscov
pose
signific
risk
public
health
secur
absenc
current
avail
effect
countermeasur
aim
assess
safeti
immunogen
candid
simian
adenovirusvector
vaccin
express
fulllength
spike
surfac
glycoprotein
mer
human
particl
highdos
group
receiv
viral
particl
primari
object
assess
safeti
toler
mer
measur
occurr
solicit
unsolicit
seriou
advers
event
vaccin
secondari
object
assess
cellular
humor
immunogen
mer
measur
enzymelink
immunospot
elisa
viru
neutralis
assay
vaccin
particip
follow
month
studi
regist
clinicaltrialsgov
find
march
aug
particip
enrol
six
assign
lowdos
group
nine
intermediatedos
group
nine
highdos
group
particip
avail
followup
month
five
one
lowdos
group
one
intermediatedos
group
three
highdos
group
lost
followup
month
singl
dose
mer
safe
dose
viral
particl
vaccinerel
seriou
advers
event
report
month
one
seriou
advers
event
report
deem
relat
mer
ci
solicit
advers
event
mild
moder
selflimit
unsolicit
advers
event
day
follow
vaccin
consid
possibl
probabl
definit
relat
mer
predominantli
mild
natur
resolv
within
followup
period
month
proport
moder
sever
advers
event
significantli
higher
highdos
group
intermediatedos
group
rel
risk
ci
p
laboratori
advers
event
consid
least
possibl
relat
studi
intervent
selflimit
predominantli
mild
sever
signific
increas
baselin
tcell
p
igg
p
respons
merscov
spike
antigen
observ
dose
neutralis
antibodi
live
merscov
observ
four
ci
nine
particip
highdos
group
day
vaccin
particip
antibodi
capabl
neutralis
pseudotyp
viru
neutralis
assay
interpret
mer
safe
well
toler
test
dose
singl
dose
abl
elicit
humor
cellular
respons
merscov
result
firstinhuman
clinic
trial
support
clinic
develop
progress
field
phase
trial
middl
east
respiratori
syndrom
coronaviru
merscov
caus
emerg
zoonot
viral
respiratori
diseas
first
describ
endem
saudi
arabia
clinic
present
merscov
infect
vari
asymptomat
sever
acut
respiratori
distress
death
merscov
sinc
spread
differ
countri
middl
east
region
laboratoryconfirm
case
merscov
infect
includ
death
countri
report
jan
merscov
pose
major
threat
public
health
secur
epidem
potenti
absenc
current
avail
effect
countermeasur
list
prioriti
pathogen
research
develop
health
agenc
around
globe
dromedari
camel
recognis
sourc
zoonot
infect
occup
exposur
associ
seroconvers
although
primari
case
associ
direct
camel
exposur
humantohuman
transmiss
especi
hospit
environ
respons
major
case
seen
outbreak
past
year
howev
sustain
humantohuman
transmiss
record
far
overal
r
role
asymptomat
mild
case
transmiss
pattern
remain
contro
versial
unclear
specif
treatment
option
licens
vaccin
current
avail
nonspecif
clinic
featur
mer
often
lead
delay
diagnosi
increas
exposur
healthcar
facil
contribut
persist
nosocomi
outbreak
complic
absenc
effect
treatment
option
suboptim
adher
infect
prevent
control
isol
practic
consid
complex
around
implement
overal
control
measur
merscov
numer
challeng
fill
knowledg
gap
requir
achiev
vaccin
remain
key
costeffect
strategi
tackl
global
merscov
threat
coronavirus
spheric
envelop
larg
positivesens
singlestrand
rna
genom
fourth
genom
respons
code
structur
protein
spike
glycoprotein
envelop
membran
nucleocapsid
protein
envelop
membran
nucleocapsid
protein
mainli
respons
virion
assembl
wherea
spike
glycoprotein
involv
receptor
bind
mediat
viru
entri
host
cell
infect
via
differ
receptor
merscov
belong
phylogenet
lineag
c
genu
betacoronaviru
recognis
dipeptidyl
peptidas
host
receptor
well
conserv
camel
human
sixth
coronaviru
known
caus
human
infect
first
human
viru
within
lineag
c
sever
acut
respiratori
syndrom
coronaviru
sarscov
respons
sar
global
epidem
sar
coronaviru
respons
current
pandem
belong
lineag
b
genu
betacoronaviru
repres
lineag
genu
betacoronaviru
wherea
belong
genu
alphacoronaviru
evid
studi
current
licens
vaccin
prevent
middl
east
respiratori
syndrom
mer
specif
therapeut
treat
mer
previous
report
immunogen
protect
mice
challeng
model
immunogen
partial
protect
dromedari
camel
natur
transmiss
model
search
pubm
research
articl
publish
databas
incept
nov
use
variou
combin
term
mer
merscov
middl
east
respiratori
syndrom
antimiddl
east
respiratori
syndrom
vaccin
phase
clinic
trial
languag
restrict
appli
one
clinic
trial
publish
describ
phase
studi
done
usa
dna
vaccin
mer
use
threedos
vaccin
regimen
intramuscular
inject
follow
colocalis
intramuscular
electropor
week
vaccin
well
toler
seroconvers
measur
elisa
occur
particip
two
vaccin
particip
three
vaccin
neutralis
antibodi
detect
particip
studi
first
clinic
studi
mer
dose
level
test
viral
particl
vaccin
safe
well
toler
major
particip
humor
cellular
mer
coronaviru
merscov
specif
immun
respons
induc
maintain
level
higher
prevaccin
respons
followup
period
studi
done
uk
vaccin
merscov
could
use
prevent
zoonot
transmiss
especi
peopl
frequent
expos
camel
middl
east
immunis
healthcar
worker
region
hospit
outbreak
occur
respond
outbreak
healthcar
set
commun
immun
correl
protect
merscov
yet
determin
speci
immunis
mer
result
rapid
induct
immun
respons
merscov
maintain
least
year
might
therefor
valu
prevent
limit
outbreak
endem
region
clinic
studi
especi
endem
region
done
vaccin
global
distribut
gener
associ
mild
respiratori
symptom
account
third
common
cold
case
spike
type
trimer
transmembran
glycoprotein
locat
surfac
viral
envelop
coronavirus
divid
two
function
subunit
ntermin
ctermin
merscov
respons
bind
host
cellular
receptor
via
viru
receptorbind
domain
rbd
fusion
viru
host
cell
mem
brane
therebi
mediat
entri
merscov
target
cell
rbd
merscov
core
structur
homolog
sarscov
receptorbind
motif
specif
merscov
determin
receptor
recognit
viral
pathogenesi
role
spike
protein
receptor
bind
membran
fusion
make
ideal
target
vaccin
antivir
develop
main
target
neutralis
antibodi
mer
consist
replicationdefici
simian
adenoviru
vector
describ
elsewher
express
codonoptimis
code
sequenc
fulllength
spike
protein
subunit
merscov
isol
camel
genbank
access
number
includ
amino
acid
ntermin
tissu
plasminogen
activ
leader
sequenc
preclin
work
shown
vaccin
highli
immunogen
anim
model
abl
induc
cellular
humor
respons
polyfunct
cell
neutralis
antibodi
singl
dose
mer
also
confer
protect
efficaci
transgen
mice
express
human
lethal
merscov
challeng
support
progress
clinic
develop
immunogen
partial
protect
efficaci
natur
transmiss
model
dromedari
camel
also
report
aim
assess
safeti
immunogen
mer
candid
merscov
vaccin
human
doseescal
openlabel
nonrandomis
un
control
phase
trial
done
centr
clinic
vaccinolog
tropic
medicin
oxford
uk
particip
recruit
advertis
healthi
peopl
age
year
neg
prevaccin
test
hiv
antibodi
hepat
b
surfac
antigen
hepat
c
antibodi
elig
particip
neg
urinari
pregnanc
test
requir
screen
immedi
enrol
women
full
detail
elig
criteria
describ
trial
protocol
provid
appendix
p
written
inform
consent
obtain
particip
trial
done
accord
principl
declar
helsinki
good
clinic
practic
studi
approv
uk
medicin
healthcar
product
regulatori
agenc
refer
south
centraloxford
research
ethic
committe
refer
vaccin
use
authoris
genet
modifi
organ
safeti
committe
oxford
univers
hospit
nation
health
servic
trust
refer
number
independ
local
safeti
monitor
provid
safeti
oversight
recombin
adenoviru
produc
previous
describ
vaccin
manufactur
accord
current
good
manufactur
practic
clinic
biomanufactur
facil
univers
oxford
oxford
uk
tetrepress
hek
cell
line
vector
vaccin
purifi
steril
filter
gener
clinic
lot
concentr
viral
particl
per
ml
mer
administ
singl
intramuscular
inject
deltoid
viral
particl
lowdos
group
viral
particl
intermediatedos
group
viral
particl
highdos
group
staggeredenrol
approach
use
first
three
particip
group
interim
safeti
review
done
dose
escal
detail
provid
appendix
p
blood
sampl
drawn
clinic
assess
done
safeti
well
immunolog
endpoint
vaccin
day
subsequ
day
vaccin
particip
observ
clinic
h
vaccin
procedur
ask
record
advers
event
use
electron
diari
followup
period
swell
inject
site
object
assess
member
studi
team
studi
visit
solicit
ie
expect
defin
protocol
local
site
reaction
inject
site
pain
warmth
red
swell
pruritu
system
symptom
malais
myalgia
arthralgia
fatigu
nausea
headach
feverish
fever
temperatur
higher
record
day
member
studi
team
particip
unsolicit
advers
event
event
defin
solicit
record
day
seriou
advers
event
record
throughout
followup
period
sever
advers
event
grade
follow
criteria
mild
mild
symptom
limit
usual
activ
moder
mildtomoder
limit
usual
activ
sever
consider
limit
activ
medic
medic
attent
requir
unsolicit
advers
event
review
causal
independ
clinician
event
consid
possibl
probabl
definit
relat
studi
vaccin
report
laboratori
advers
event
grade
use
sitespecif
toxic
tabl
adapt
see
onlin
appendix
us
food
drug
administr
toxic
grade
scale
total
antim
spike
igg
determin
humor
immun
measur
use
standardis
inhous
indirect
elisa
merscov
neutralis
antibodi
nunc
maxisorp
plate
life
technolog
paisley
uk
coat
fulllength
recombin
clamp
mer
spike
protein
suppli
keith
chappel
school
chemistri
molecular
bioscienc
univers
queensland
brisban
qld
australia
phosphat
buffer
salin
incub
h
overnight
coat
plate
wash
six
time
phosphat
buffer
salinetween
block
casein
h
room
temperatur
plasma
sampl
dilut
fall
within
linear
rang
curv
typic
casein
ad
individu
well
plate
step
follow
incub
plate
room
temperatur
h
wash
plate
initi
describ
plate
incub
room
temperatur
h
secondari
antibodi
alkalin
phosphataseconjug
goat
antihuman
igg
specif
final
wash
plate
develop
ad
phosphat
diethanolamin
substrat
buffer
fisher
scientif
uk
loughborough
uk
standard
curv
use
plate
deriv
pool
volunt
sera
contain
hightitr
antim
igg
endpoint
titr
determin
elisa
use
identifi
volunt
sampl
highest
antim
igg
titr
vaccin
dilut
standard
pool
use
twofold
serial
dilut
produc
ten
standard
point
assign
arbitrari
elisa
unit
optic
densiti
valu
standard
point
fit
fourparamet
hyperbol
curv
arbitrari
elisa
unit
use
softwar
version
biotek
instrument
winooski
vt
usa
paramet
estim
standard
curv
use
convert
absorb
valu
individu
test
sampl
elisa
unit
elisa
plate
consist
sampl
intern
posit
control
dilut
standard
pool
correspond
standard
triplic
ten
standard
point
duplic
four
blank
well
optic
densiti
read
plate
nm
done
micropl
reader
biotek
instrument
neutralis
antibodi
live
merscov
measur
use
pair
serum
sampl
obtain
day
day
induct
virusneutralis
antibodi
confirm
accord
previous
publish
protocol
briefli
serum
sampl
test
capac
neutralis
merscov
isol
infect
vitro
tissu
cultur
infect
dose
cell
sera
incub
h
viru
ad
cell
incub
day
recombin
human
monoclon
antibodi
direct
rbd
merscov
creativ
biolab
shirley
ny
usa
serv
neutra
lisat
control
full
neutralis
observ
dilut
without
one
dilut
step
accept
interassay
variat
correspond
concentr
neutralis
titr
calcul
reciproc
valu
geometr
mean
titr
four
replic
titr
consid
posit
pseudoviru
neutralis
assay
merscov
endoplasm
reticulum
retent
signaldelet
amino
acid
pseudotyp
lentivir
particl
gener
titrat
use
lentivirusassoci
elisa
kit
cell
biolab
san
diego
ca
usa
twofold
dilut
serum
incub
viral
particl
pseudotyp
viru
min
ad
cell
incub
h
replac
fresh
medium
luciferasereport
activ
measur
day
later
assess
cellular
immun
enzymelink
immunospot
elispot
assay
done
fresh
peripher
blood
mononuclear
cell
pbmc
determin
respons
merscov
spike
vaccin
antigen
methodolog
describ
previous
follow
except
pbmc
separ
whole
blood
within
h
venepunctur
synthet
peptid
overlap
ten
amino
acid
span
entir
vaccin
insert
includ
tissu
plasminogen
activ
leader
sequenc
use
stimul
pbmc
peptid
pool
pool
merscov
spike
protein
contain
peptid
plu
singl
pool
five
peptid
tissu
pla
minogen
activ
leader
peptid
sequenc
pool
summaris
appendix
pp
data
analys
accord
qualiti
control
standard
oper
procedur
lower
limit
detect
assay
spotform
cell
sfc
sum
respons
merscov
spike
peptid
pool
primari
outcom
occurr
solicit
local
reactogen
sign
symptom
day
vaccin
occurr
solicit
system
reactogen
sign
symptom
day
vaccin
occurr
unsolicit
advers
event
day
vaccin
chang
day
baselin
day
safeti
haematolog
full
blood
count
biochemistri
sodium
potassium
urea
creatinin
bilirubin
alanin
aminotransferas
alkalin
phosphatas
albumin
laboratori
measur
occurr
seriou
advers
event
whole
studi
durat
month
secondari
outcom
cellular
humor
immunogen
mer
measur
elispot
elisa
virusneutralis
antibodi
assay
baselin
month
safeti
endpoint
describ
frequenc
respect
percentag
alongsid
ci
associ
frequenc
moder
sever
solicit
advers
event
group
alloc
inter
mediat
dose
high
dose
report
rel
risk
respect
ci
p
valu
fisher
exact
test
immunolog
data
test
normal
distri
bution
use
dagostinopearson
omnibu
normal
test
data
analys
nonparametr
measur
data
normal
distribut
sampl
size
small
kruskalw
dunn
multipl
com
parison
post
test
use
compar
across
timepoint
group
p
valu
less
consid
signific
elispot
data
valu
sfc
per
million
pbmc
statist
analysi
safeti
immunogen
data
done
graphpad
prism
version
window
studi
regist
clinicaltrialsgov
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
inject
site
pain
common
local
advers
event
report
particip
predominantli
mild
sever
tabl
fatigu
common
system
advers
event
follow
headach
malais
median
durat
solicit
advers
event
summaris
appendix
p
six
particip
report
shortliv
fever
temperatur
higher
within
first
h
vaccin
one
intermediatedos
group
five
highdos
group
one
particip
highdos
group
temperatur
class
sever
fever
day
vaccin
result
vaccin
episod
resolv
within
h
proport
moder
sever
advers
event
significantli
higher
highdos
group
intermediatedos
group
rel
risk
ci
p
safeti
concern
despit
higher
reactogen
unsolicit
advers
event
day
follow
vaccin
consid
possibl
probabl
definit
relat
mer
predominantli
mild
natur
resolv
within
followup
period
month
appendix
p
laboratori
advers
event
consid
least
possibl
relat
studi
intervent
selflimit
predominantli
mild
sever
appendix
p
singl
dose
vaccin
induc
strong
antibodi
respons
particip
across
group
persist
year
vaccin
particip
lost
followup
antibodi
respons
increas
rapidli
vaccin
peak
day
vaccin
group
figur
igg
titr
increas
significantli
day
day
vaccin
increas
mer
dose
compar
baselin
figur
appendix
p
signific
differ
antim
igg
found
dose
group
timepoint
data
shown
detect
antim
igg
titr
observ
four
particip
baselin
howev
baselin
respons
inhibit
antibodi
respons
vaccin
evid
increas
igg
titr
observ
particip
day
day
vaccin
appendix
p
neutralis
antibodi
live
merscov
measur
particip
five
lowdos
group
eight
intermediatedos
group
nine
highdos
group
viru
neutralis
antibodi
titr
measur
day
neg
day
neutralis
antibodi
detect
lowdos
group
one
five
particip
highdos
group
four
ci
nine
particip
highdos
group
produc
signific
increas
neutralis
antibodi
titr
compar
baselin
p
kruskallw
dunn
multipl
comparison
test
figur
assay
test
neutralis
live
merscov
heterolog
vaccinederiv
strain
exploratori
investig
associ
total
igg
neutralis
antibodi
titr
highdos
group
peak
antibodi
respons
show
moder
posit
correl
total
igg
neutralis
antibodi
titr
appendix
p
neutralis
test
three
pseudotyp
lentivirus
express
spike
glycoprotein
three
differ
merscov
strain
neg
day
ci
sampl
posit
day
test
ci
posit
test
day
figur
neutralis
antibodi
titr
measur
live
mer
viru
highdos
group
correl
significantli
measur
use
three
differ
pseudotyp
lentivir
particl
appendix
p
cellular
immunogen
mer
assess
exvivo
elispot
respons
neg
control
pbmc
stimul
low
median
sfc
iqr
expect
respons
exogen
tissu
plasminogen
leader
sequenc
detect
median
sfc
iqr
data
shown
high
frequenc
cell
recognis
mer
spike
peptid
elicit
figur
data
six
assay
remov
final
dataset
neg
control
predefin
qualiti
control
paramet
respons
peak
figur
signific
effect
vaccin
dose
magnitud
respons
detect
timepoint
therefor
data
pool
subsequ
analys
observ
signific
increas
tcell
respons
investig
rel
contribut
individu
peptid
pool
peak
timepoint
day
identifi
region
immunodomin
within
antigen
figur
pool
frequent
recognis
respons
subunit
higher
day
particip
appendix
p
tcell
respons
rbd
within
persist
day
vaccin
appendix
p
detect
respons
mer
spike
peptid
vaccin
geometr
mean
sfc
ci
figur
appendix
p
four
particip
one
lowdos
group
three
intermediatedos
group
mainli
toward
rbd
peptid
pool
appendix
p
correl
found
magnitud
preexist
postvaccin
respons
day
spearman
figur
associ
day
respons
hla
type
detect
data
shown
associ
magnitud
preexist
tcell
immun
humor
respons
measur
day
associ
magnitud
tcell
antibodi
respons
mer
day
spearman
appendix
p
studi
shown
candid
mer
vaccin
given
singl
dose
safe
well
toler
three
group
although
higher
reactogen
profil
observ
dose
viral
particl
five
nine
particip
group
report
shortliv
fever
temperatur
higher
seriou
advers
reaction
occur
major
advers
event
report
mild
moder
sever
advers
event
selflimit
profil
advers
event
report
trial
similar
anoth
vector
vaccin
express
influenza
antigen
close
relat
simian
adenovirus
vector
vaccin
express
differ
antigen
safeti
concern
around
use
fulllength
coronaviru
spike
glycoprotein
vaccin
antigen
rais
follow
histor
report
immunopatholog
antibodydepend
enhanc
report
vitro
postsarscov
challeng
mice
ferret
nonhuman
primat
immunis
whole
sarscovinactiv
fulllength
spike
proteinbas
vaccin
far
one
studi
report
lung
immunopatholog
follow
merscov
challeng
mice
immunis
inactiv
merscov
candid
vaccin
howev
preclin
studi
immunis
merscov
challeng
antibodydepend
enhanc
observ
transgen
mice
express
human
dromedari
camel
nonhuman
primat
vaccin
immunogen
dose
induc
seroconvers
major
particip
tcell
respons
respons
demonstr
good
durabl
year
vaccin
onset
detect
immun
respons
rapid
tcell
respons
peak
day
vaccin
antibodi
day
small
number
particip
posit
antibodi
tcell
respons
never
vaccin
preexisit
respons
like
due
crossreact
known
human
coronavirus
circul
worldwid
caus
lower
respiratori
tract
infect
preval
seroposit
four
virus
uk
unknown
crosssect
survey
netherland
found
children
sero
convert
least
one
age
year
like
rate
similar
uk
emerg
preexist
crossreact
immun
respons
human
coronavirus
like
area
investig
importantli
preexist
tcell
antibodi
respons
affect
vaccin
immunogen
neutralis
antibodi
detect
vaccin
correl
protect
merscov
current
unknown
neutralis
antibodi
target
differ
epitop
spike
glycoprotein
associ
protect
merscov
challeng
anim
model
demonstr
singl
dose
mer
abl
elicit
neutralis
antibodi
live
merscov
particip
receiv
high
dose
particip
produc
neutralis
antibodi
assay
use
pseudotyp
lentivirus
express
spike
glyco
protein
three
differ
strain
merscov
despit
differ
methodolog
strong
posit
correl
neutralis
antibodi
pseudotyp
virus
neutralis
antibodi
obtain
live
viru
assay
highdos
group
strategi
increas
neutralis
antibodi
seroconvers
includ
twodos
regimen
investig
hypothesi
underway
importantli
mer
survivor
tcell
respons
found
correl
less
sever
diseas
lower
viru
shed
mer
vaccin
result
signific
increas
mer
spikespecif
tcell
respons
maintain
least
year
vaccin
four
time
higher
baselin
adenovir
vector
vaccin
potent
induc
tcell
respons
phenotyp
cell
induc
vaccin
determin
studi
merscov
vaccin
requir
camel
human
mer
test
dromedari
camel
saudi
arabia
shown
significantli
reduc
viral
shed
could
potenti
translat
reduc
zoonot
transmiss
one
health
vaccin
develop
approach
use
vaccin
codevelop
human
suscept
anim
speci
allow
vaccin
efficaci
test
appropri
anim
model
could
support
licensur
vaccin
human
target
group
includ
peopl
occup
expos
camel
healthcar
worker
howev
sever
fatal
case
merscov
disproport
affect
individu
older
year
comorbid
therefor
paramount
vaccin
develop
merscov
suitabl
administr
older
age
group
context
outbreak
use
replicationdefici
vector
avoid
risk
inadequ
attenu
replicationcompet
vaccin
could
potenti
lead
dissemin
diseas
immuno
compromis
host
immunogen
vector
vaccin
influenza
demonstr
older
adult
year
age
use
outbreak
rapid
onset
immun
singl
dose
demonstr
highli
desir
coalit
epidem
prepared
innov
support
clinic
develop
four
novel
vaccin
mer
express
fulllength
spike
glyco
protein
addit
mer
dna
vaccin
two
viral
vector
vaccin
mva
measl
vector
develop
data
earli
clinic
trial
support
use
one
vaccin
middl
east
stockpil
suitabl
outbreak
respons
countri
limit
studi
includ
small
sampl
size
openlabel
nonrandomis
uncontrol
trial
design
longterm
safeti
immunogen
find
interpret
caution
consid
five
particip
declin
extend
followup
research
requir
better
understand
import
preexist
immun
crossreact
coronavirus
context
emerg
coronavirus
outbreak
nonetheless
studi
provid
valuabl
inform
reactogen
immunogen
first
clinic
use
mer
conclus
mer
safe
well
toler
test
dose
singl
dose
abl
elicit
humor
cellular
respons
merscov
result
firstinhuman
clinic
trial
support
clinic
develop
progress
phase
trial
middl
east
healthi
adult
healthcar
worker
peopl
occup
expos
camel
older
age
group
comorbid
recruit
assess
safeti
immunogen
mer
given
singl
twodos
administr
regimen
studi
design
pmf
ah
ke
sg
pmf
frl
js
ds
ip
md
jm
yt
collect
studi
data
oversaw
particip
visit
al
provid
regulatori
oversight
ab
nt
rr
provid
project
manag
immunogen
test
done
mb
af
db
ak
cm
cr
sh
rm
js
interpret
mb
af
sb
ke
analysi
sampl
pseudotyp
neutralis
assay
design
jok
ms
assay
done
yj
ysp
interpret
jok
ms
mb
safeti
data
analysi
interpret
done
pmf
clinic
trial
data
manag
done
pmf
ip
pmf
mb
af
sg
wrote
manuscript
author
contribut
review
edit
report
approv
final
version
ah
sg
cofound
consult
sharehold
vaccitech
develop
adenovir
vector
vaccin
pmf
tl
consult
vaccitech
author
declar
compet
interest
studi
protocol
avail
public
part
supplementari
materi
individu
particip
data
avail
upon
request
direct
correspond
author
approv
propos
share
secur
onlin
platform
